Pharmaxis prescribes a shake-up to fix FDA woes
Australian drug maker Pharmaxis has replaced its long-serving chief executive Alan Robertson as it looks to shift focus away from development towards the commercialisation of its cystic fibrosis treatment Bronchitol.
The biotech firm said Dr Robertson would be replaced immediately by chief operating officer Gary Phillips, who would review Pharmaxis' business model.
Two months ago, Pharmaxis was hit by a set-back when advisers to US regulators negatively reviewed Bronchitol. That has made it less likely the Food and Drug Administration would approve the drug for the US market later this month.
"Pharmaxis is facing likely delays in the commercialisation of Bronchitol in the United States," chairman Malcolm McComas said. "Gary Phillips will review the current business model and implement a number of changes."
Pharmaxis shares closed 8.4 per cent lower on Tuesday at 55¢.
Mr Phillips has served as an executive of Swiss pharmaceutical company Novartis and is a three-decade veteran of the sector.
He said the firm had to focus on maximising the growth of Bronchitol's sales in Europe and Australia, while working to enter new markets in eastern Europe, the Middle East and South America.
Deutsche Bank healthcare analyst Nicholas Cameron said Mr Phillips was a "very good candidate" with a wealth of experience in commercially oriented roles.
However Mr Cameron said he expected significant risks to remain with the company in the longer term, given the expected delays in the US approval of Bronchitol.
Mr Phillips said he was planning to work with the FDA to gain approval for Bronchitol, and with the Australian government to help improve the take-up of Bronchitol by patients.
InvestSMART FORUM: Come and meet the team
We're loading up the van and going on tour from April to June, with events on the NSW central & north coast, the QLD mid-north coast and in Perth, Adelaide, Melbourne, Sydney and Canberra. Come and meet the team and take home simple strategies that you can use to build an investment portfolio to weather any storm. Book your spot here.
Want access to our latest research and new buy ideas?
Start a free 15 day trial and gain access to our research, recommendations and market-beating model portfolios.Sign up for free